Some digital programs are designed to treat specific ADHD-related attention difficulties. Others provide reminders, planning support, or practice on memory tasks.
These tools can look similar, but their purposes and evidence differ. Before investing time or money, ask what a particular tool has been shown to help and whether that matches what you need.
Better performance on an attention test does not automatically mean everyday life becomes easier. Look for evidence about daily functioning as well as test scores.
Research and Lived Experience Answer Different Questions
Research helps assess whether a product produces benefits under the conditions studied. Your lived experience helps assess whether its schedule, sensory demands, cost, and effects fit your daily life. Both belong in a decision about continuing a tool.
What Is a Digital Therapeutic?
A digital therapeutic uses software as a health intervention. Some are regulated medical devices with a defined use, age range, treatment schedule, and safety information.
A reminder app can be useful without being a medical treatment. A game that trains memory is not automatically an ADHD treatment. The evidence needs to match the exact product and the claim being made.
What Does the Research Show?
A 2023 review combined 31 studies involving 2,169 children and adolescents ages 4–17. It found a small average improvement in inattention and improvements on some measures of executive functioning and working memory. The combined result for hyperactivity and impulsivity was not statistically significant. He and colleagues, 2023
Executive functioning refers to processes used to plan, organize, begin, and manage activities. Working memory helps you hold information in mind while using it.
The review covered different interventions and measures. Its findings do not establish that every ADHD app works. Most participants were boys, and none were adult women, so this review cannot establish benefits specifically for ADHD women. Read the review
Three FDA-Reviewed Products
The following are U.S. regulatory indications. Clearance describes a specific use; it does not guarantee benefit for every person or every ADHD difficulty.
Product | Who the indication covers | What it targets |
EndeavorRx | Ages 8–17; prescription; primarily inattentive or combined-type ADHD with a demonstrated attention difficulty. | Attention measured by computerized testing. |
EndeavorOTC | Adults 18 and older; over the counter; primarily inattentive or combined-type ADHD with a demonstrated attention difficulty. | Attention measured by computerized testing. |
Prismira, marketed as LumosityRx | Adults ages 22–55; prescription; primarily inattentive or combined-type ADHD. | Attention, including sustained and selective attention measured by computerized testing. |
Sources: EndeavorRx FDA summary, EndeavorOTC FDA summary, and Prismira FDA summary. The manufacturer identifies LumosityRx as Prismira’s commercial name. LumosityRx information
EndeavorRx
EndeavorRx is a prescription game. Its age indication expanded from 8–12 to 8–17 in 2023. Its labeling explains that improvement in tested attention may not be accompanied by improvement in behaviors such as hyperactivity. It is intended to fit within a broader treatment program. FDA summary
EndeavorOTC
The adult product received FDA clearance in 2024. Its pivotal adult study had a single treatment group and no sham comparison group.
A sham comparison uses a similar-looking program without the same active training. Without one, it is harder to separate treatment effects from other reasons scores may improve. The FDA summary explicitly identifies this limitation. FDA summary
LumosityRx / Prismira
Prismira received FDA clearance in 2025. Its nine-week study used random assignment and a sham comparison. Attention-test performance improved more in the treatment group.
However, the treatment group’s average improvement was below the attention test’s cited threshold for a clinically important change. A statistically significant result does not necessarily mean a large or noticeable benefit for an individual. FDA summary
The general Lumosity brain-training app is a different product. Its subscription should not be assumed to provide the prescription treatment. At this page’s September 13, 2026 review, the LumosityRx website was inviting people to join a waitlist. FDA clearance and availability are separate questions. Manufacturer information
What About Watches, VR, and Other Brain-Training Tools?
Wearable reminders: a watch can provide an external cue to check the time or return to an activity. A reminder does not necessarily mean the device can detect whether you are paying attention. For products such as Revibe, check the exact model, how prompts are generated, and whether claims come from controlled research or customer reports.
Virtual reality: VR programs, including NeuroTrainer, may be marketed for cognitive or performance training. Evidence from athletes or people without ADHD does not establish an ADHD treatment benefit. Ask for research on the actual program in the population it is being recommended for.
Cognitive training: practicing a memory or attention task may improve performance on that task. The next question is whether the benefit carries over to something you need to do outside the program. Researchers call that transfer.
These categories should not be treated as interchangeable with the FDA-reviewed products above.
Questions to Ask Before Trying a Tool
- What do I want help with? For example, following instructions, beginning work, or remembering appointments.
- Who was studied? Children, adults, and people with other conditions may respond differently.
- What improved? Game scores, a separate attention test, symptoms, daily functioning, or quality of life?
- Was there a comparison group? Did researchers know who received the treatment?
- Who funded the research? Has another research team reproduced the result?
- What does using it require? Consider time, cost, equipment, sensory demands, and remembering sessions.
- What are the safety and privacy terms? Read the product’s current labeling and data policy.
Follow product-specific guidance with an appropriate clinician. For example, the FDA documents include limits relevant to photosensitive epilepsy and difficulty using a mobile device. EndeavorOTC labeling and Prismira labeling
Evaluate Whether It Helps Your Life
Choose one everyday outcome before starting. You might track whether you can follow a meeting more easily or complete a chosen task with less effort.
Agree on a review point using the recommended treatment schedule. Consider the benefit alongside the effort, frustration, cost, and effect on sleep or other activities.
A useful tool should support your priorities. It should not become another standard you have to meet to prove that you are trying. Accommodations, appropriate treatment, and changes to unrealistic demands remain relevant whether or not you use an app.
Evidence and regulatory information reviewed September 13, 2026.